Targeting this TGF-β/SMAD3/ATF4 axis or directly inhibiting CBS effectively suppressed cysteine secretion, reversed ferroptosis resistance, and sensitized PDAC to chemotherapy in vitro and in vivo, offering novel therapeutic strategies for treating pancreatic cancer. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.